Streetbeat News

Analyst Ratings

NTLA

Chardan Capital analyst Geulah Livshits maintains a Buy rating on Intellia Therapeutics (NASDAQ:NTLA) but lowers the price target from $111 to $107.

Portfolio Pulse from richadhand@benzinga.com

June 13, 2023 | 12:04 pm

ESNT

In the last quarter, Essent Group (NYSE:ESNT) received three somewhat bullish analyst ratings and one indifferent rating, with an average price target of $49.75, implying an upside compared to the current price of $46.34. The average price target has increased by 1.53% over the past month.

Portfolio Pulse from Benzinga Insights

June 13, 2023 | 12:04 pm

ORTX

Oppenheimer analyst Kevin DeGeeter maintains an Outperform rating on Orchard Therapeutics (NASDAQ:ORTX) but lowers the price target from $37 to $34.

Portfolio Pulse from richadhand@benzinga.com

June 13, 2023 | 12:03 pm

EOG

In the last quarter, EOG Resources (NYSE:EOG) received 9 bullish, 6 somewhat bullish, and 2 indifferent ratings from analysts. The average 12-month price target for EOG is $144.71, a 2.69% decrease from the previous average of $148.71.

Portfolio Pulse from Benzinga Insights

June 13, 2023 | 12:03 pm

JEF

Oppenheimer analyst Chris Kotowski maintains an Outperform rating on Jefferies Financial Gr (NYSE:JEF) and raises the price target from $40 to $45.

Portfolio Pulse from richadhand@benzinga.com

June 13, 2023 | 12:01 pm

TRTX

JMP Securities analyst Steven Delaney reiterated a Market Outperform rating on TPG RE Finance Trust (NYSE:TRTX) and maintained a $10 price target.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2023 | 12:01 pm

GXO

Credit Suisse analyst Ariel Rosa maintains an Outperform rating on GXO Logistics (NYSE:GXO) and raises the price target from $65 to $68.

Portfolio Pulse from richadhand@benzinga.com

June 13, 2023 | 12:00 pm

OCUL

JMP Securities analyst Jonathan Wolleben reiterated a Market Outperform rating on Ocular Therapeutix (NASDAQ:OCUL) and maintained a $12 price target.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2023 | 12:00 pm

NTLA

Credit Suisse analyst Richard Law reiterated an Outperform rating on Intellia Therapeutics (NASDAQ:NTLA) and maintained a $76 price target.

Portfolio Pulse from richadhand@benzinga.com

June 13, 2023 | 12:00 pm

KURA

JMP Securities analyst Reni Benjamin reiterated a Market Outperform rating on Kura Oncology (NASDAQ:KURA) and maintained a $22 price target.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2023 | 11:59 am